When endometrial cancer returns after initial treatment, patients face a grim reality: their options have long been limited and outcomes poor. But a new drug called sacituzumab tirumotecan (sac-TMT) is changing that calculus. Merck announced Monday that the investigational treatment achieved statistically significant improvements in both overall survival and progression-free survival in a Phase 3 clinical trial called TroFuse-005—the first global trial to demonstrate such survival gains in patients with advanced or recurrent endometrial cancer compared to standard chemotherapy.
The stakes are high. Endometrial cancer is one of the few malignancies that are increasing in both incidence and mortality worldwide, making this development particularly urgent. In the United States, deaths from endometrial cancer now exceed deaths from ovarian cancer, making it the deadliest of all gynecologic malignancies. Dr. Brian Slomovitz, co-director of gynecologic oncology at Mount Sinai and an investigator on the trial, emphasizes the scale of the problem: patients whose disease progresses after platinum chemotherapy and immunotherapy "are urgently in need of new options."
The TroFuse-005 trial enrolled 776 patients whose endometrial cancer had worsened despite receiving both platinum chemotherapy and immunotherapy—a particularly challenging population. Half received sac-TMT, administered every two weeks by intravenous infusion, while the other half received treatment of the physician's choice, typically doxorubicin or paclitaxel. Patients knew which treatment they were receiving. Those receiving sac-TMT showed what researchers describe as "clinically meaningful improvement" in their disease state, meeting the trial's primary endpoints for both overall and progression-free survival. The drug also met response rate benchmarks and showed a similar side effect profile to earlier studies.
Sac-TMT belongs to a class of drugs called antibody-drug conjugates (ADCs)—targeted therapies that deliver powerful medications directly to tumor cells while limiting damage to healthy tissue. This represents the first and only ADC to achieve such survival improvements for endometrial cancer patients in this setting. The drug targets TROP2, a protein found on cancer cells, making it a precision approach rather than blanket chemotherapy.
Dr. Domenica Lorusso, the study's global lead investigator and professor of obstetrics and gynecology at Humanitas University in Milan, notes that these results address "a critical unmet need for certain patients with advanced endometrial cancer." She highlighted the particular importance: "Despite recent advances, patients whose disease progresses following treatment with platinum and immunotherapy are urgently in need of new options, and these findings show for the first time that a TROP2 ADC may be an effective option in this setting."
While Merck has not yet released specific survival statistics, response rates, or detailed side effect data—those will come when researchers present full results at an upcoming medical meeting—the significance of the announcement is clear. As Slomovitz notes, "an overall survival improvement in recurrent disease is a real, meaningful result for patients and their families, not just a statistical one." For endometrial cancer patients facing recurrence, that represents genuine hope where options have been scarce.